BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $13.50 Average PT from Analysts : vimarsana.com

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the seven analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month target price […]

Related Keywords

Canada , United States , America , , Needham Company , Ghost Tree Capital , News Ratings For Biocryst Pharmaceuticals Daily , Biocryst Pharmaceuticals , Commerce Bank , Biocryst Pharmaceuticals Inc , Royal Bank , Nasdaq , Jefferies Financial Group , Biocryst Pharmaceuticals Trading Down , Institutional Trading Of Biocryst Pharmaceuticals , Analyst Recommendations For Biocryst Pharmaceuticals , Biocryst Pharmaceuticals Company Profile , Artisan Partners Limited Partnership , Get Free Report , Financial Group , Cryst Pharmaceuticals Trading Down , Cryst Pharmaceuticals , Asset Management , Partners Limited Partnership , Tree Capital , Get Free , Biocryst Pharmaceuticals Daily , Nasdaq Bcrx , Bcrx , Medical , 09058v10 , Ratings , Consensus ,